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Abstract
Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy that affects
women from puberty to whole reproductive life. Diagnosis and treatment of PCOS is
not clear. Polycystic ovary syndrome is a multisystem disease that involves dermatolo-
gist examining patients with clinical hyperandrogenism and/or biochemical signs of
hyperandrogenism; gynecologist examines patients with oligo-ovulation or infertility.
The management of PCOS should be tailored to each woman’s specific symptoms,
fertility-related implications, and metabolic disorders. Pharmacologic treatment is not
necessary for all patients with PCOS, also lifestyle changes like exercise, weight loss, and
diet are effective for treatment. Lifestyle changes are often recommended as first-line
treatment for PCOS to benefit general health. Topical nonhormonal therapies and laser
hair removal may be effective for cutaneous symptoms like acne, hirsutism, and andro-
genetic alopecia in the PCOS population and are useful first-line agents. Some pharma-
cological agents (anti-androgens) are used to control the dermatological symptoms of
hyperandrogenism. Metformin is useful for metabolic and glycemic anomalies and for
the treatment of menstrual irregularities, but less effective than antiandrogens for the
treatment of both hirsutism and acne. The aim of this study is to talk about unclear
topics in PCOS and multidisciplinary approach to patients.
Keywords: polycystic ovarian syndrome, hyperandrogenism amenorrhea, hirsutism,
infertility
1. Introduction
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder among women
of reproductive age but often unrecognized condition. It was first described by Stein and
Leventhal in 1935 as women with polycystic ovaries, amenorrhea, and hirsutism [1]. One in
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15 women worldwide is affected by this syndrome [2]. There is actually no consensus on
diagnostic criteria and the figures may change.
Most women with PCOS have infertility or subfertility and other metabolic alterations such as
insulin resistance, dyslipidemia, hyperinsulinemia, and obesity. Despite the etiology of the
syndrome is still far from being elucidated, it could be considered the result of concurrent
endocrine modifications, lifestyle factors, and genetic background. In particular, accumulating
evidence suggests that insulin resistance and compensatory hyperinsulinemia play a pivotal
pathogenic role in the hyperandrogenism of many PCOS phenotypes, which in turn have a
clear detrimental effect on chronic anovulation [3].
There has been considerable controversy about specific diagnostic criteria when all classic
features (hirsutism, irregular menstrual cycles, obesity, and a classic ovarian morphology by
transvaginal ultrasonography) are not evident.
Research for PCOS in the last decade has brought new important insights for the evaluation
and treatment of this disorder. Unclear points for diagnosis and treatment and proper
approach to PCOS-related diseases will be discussed in this chapter.
2. Diagnosis
Some criteria have been proposed for the diagnosis of the disease but these criteria have
changed several times. In fact, clinically recognized hyperandrogenism and the non-regularity
of ovarian function, especially chronic anovulation, are the main criteria. Hirsutism, acne, and
alopecia are clinical signs of hyperandrogenism in these women while it may be difficult to
make a diagnosis due to phenotype, obesity, race/ethnicity, and environmental factors. Most of
these women have polycystic ovaries that can be shown in imaging studies, but this is not a
criterion for diagnosis because many healthy women may have polycystic ovaries. The diag-
nosis of the polycystic ovary was also revised. Most of the researchers used the presence of at
least 12 follicles (measuring 2–9 mm in diameter) in each ovarian as a criterion prior to 2014.
Dewailly et al. reported that the threshold value of ≥25 follicles is significant for diagnosis [4].
In addition, it is not uncommon for PCOS to coexist with obesity, insulin resistance,
dyslipidemia, endothelial dysfunction, and other metabolic disorders. All of these suggests
metabolic syndrome.
2.1. Diagnostic criteria
According to 1990 National Institutes of Health (NIH) criteria, hyperandrogenemia findings
and ovulation disorder were defined as PCOS. In 2003, Rotterdam criteria for PCOS diagnosis
were accepted by the NIH (Table 1) [5].
General agreement exists among specialty society guidelines that the diagnosis of PCOS must
be based on the presence of at least two of the following three criteria: chronic anovulation,
hyperandrogenism (clinical or biological), and polycystic ovaries [6].
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2.1.1. Detecting of ovulatory dysfunction
The definition of ovulatory dysfunction is not clear. If the menstrual cycle length is longer than
35 days, it is assumed that chronic anovulation is present and that special tests are not needed.
A 30–35 day cycle can also be anovulatory. Measurement of serum progesterone in the mid-
luteal stage (Days 21–22) is the best way to evaluate ovulation. Progesterone levels > 2.5 ng/mL
may indicate ovulation but values of ≥7 ng/mL are needed for normal luteal function [7]. Three
consecutive measurements with a total serum value of ≥15 ng/mL indicate normal luteal
function. Alternatives to progesterone measurement such as baseline body temperature sched-
ules, urinary luteinizing hormone (LH) kits, or timed endometrial biopsy may be suggested,
but do not provide sufficient information about the luteal phase. The cycle time for
oligomenorrhea is ≥35 days in adult women. The threshold value during puberty is higher
and a cycle length of up to 40 days can be considered normal.
2.1.2. Measurement of androgens
In women, the androgen source is the adrenal cortex and the ovaries. Testosterone is produced
from the ovary, DHEA-S is produced from the adrenal gland, and androstenedione is pro-
duced from both adrenal and ovarian.
The issue of which serum androgen should be measured for diagnosis of PCOS remains
controversial. Free testosterone (T) levels are more sensitive than the measurement of total T
for establishing the existence of androgen excess. The normal value of total testosterone level is
20–60 ng/dl. In cases with PCOS, the total testosterone level is generally lower than 150 ng/dl.
If the total testosterone level is higher than 150 ng/dl, testosterone-secreting adrenal tumor,
ovarian tumor, or ovarian hypertrophy should be suspected. In patients using oral contracep-
tives, total androgen levels should be measured 8–12 weeks after drug withdrawal.
Direct analog RIA measurement in commercial laboratories is notoriously inaccurate. Ideally,
it should be determined through equilibrium dialysis techniques. Consequently, if the clinician
is uncertain regarding the quality of the free-T assay, it may be preferable to rely on calculated
free T, which has a good concordance and correlation with free T as measured by equilibrium
dialysis methods [8]. Value of measuring levels of androgens other than T (dehydroepiandros-
terone sulfate, androstenedione) in patients with PCOS is relatively insignificant. If dehydroe-
piandrostenedione sulfate (DHEAS) levels are higher than 700 μg/dL, adrenal tumors should
be suspected. DHEAS levels may also increase in cases with LOCAH (late-onset congenital
adrenal hyperplasia), Cushing’s disease, adrenal adenomas as well as PCOS.
NIH 1990 criteria Rotterdam criteria [5] AE-PCOS Society criteria
Hyperandrogenism Required Two of three required Required
Ovulatory dysfunction
(oligo- or amenorrhea)
Required Two of three required Either ovulatory dysfunction
or PCOS morphology required
PCOS morphology Not required Two of three required Either ovulatory dysfunction
or PCOS morphology required
Table 1. Diagnostic criteria for PCOS.
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2.2. Other laboratory tests
Patients with non-classical 21-hydroxylase deficiency may develop as PCOS hyperandrogenism,
anovulation, and PCO. Therefore, evaluation of serum 17 hydroxyprogesterone (17OH-PG)
should be always included in a diagnostic study [9, 10]. Serum 17OH-PG levels higher than
10 ng/mL indicates the presence of 21-hydroxylase deficiency, while values between 2 and 10 ng/
mL suggest that further testing with adrenocorticotropic hormone stimulation is needed [10].
Serum AMH > 5 ng/mL is also reported to be significant for PCOS [11].
2.2.1. Evaluation of ovarian morphology
Ovarian morphology is usually evaluated by transvaginal ultrasonography. Transabdominal
ultrasonography may be used for virgin patients, but ovarian morphology assessment and
especially the calculation of the number of small follicles may be difficult. Ultrasonographic
imaging technology has been rapidly developing and the clinician should know that the number
of follicles visible is related to ultrasound quality [4]. According to current Rotterdam guidelines,
PCO is defined as the presence of at least 12 follicles measured 2–9 mm or an increased ovarian
size (>10 mL) (Figure 1) [12]. The new AES guidelines, based on the observation of published
data using new ultrasound technology, increased the threshold number of small ovarian follicles
to 25 [4]. The ovarian size threshold is unaffected by new technologies and the threshold between
normal and increased ovarian size is assumed to be 10 mL. In some populations, during puberty
or aging, a different threshold for ovarian size may be suggested [13].
2.2.2. Clinical signs of hyperandrogenism
Hirsutism is defined as excessive hair growth in women in a manner consistent with androgen
sensitivity. Typically, hirsutism in PCOS is followed by initial menarche, whereas in some of the
adolescent girls, pubic hair development and hirsutism had already begun 25–33% of white
women have terminal hair on the upper lip, periareolar area or linea-alba, but hirsutism and
various other hyperandrogenic disorders are more prominent in PCOS. The presence of substan-
tial numbers of terminal hairs over the chin, neck, lower face, and sideburns (particularly if
extending medially) indicates the presence of androgen excess. It should be noted that ethnic
differences in the number of hair follicles present and individual skin sensitivity of the
Figure 1. Transvaginal sonographic view of a polycystic ovary syndrome patient (Işık Kaban M.D. photo archive).
Debatable Topics in PCOS Patients12
pilosebaceous unit to androgens are major determinants of the presence of hirsutism, as well as
acne and androgenic alopecia (Figures 2–5) [14]. Ferriman-Gallwey scale has been the most
widely used for evaluating hirsutism, but it is limited by its subjective nature and failure to
include the sideburn, perineal, or buttock areas [15]. In this system, nine regions in the body are
Figure 2. Androgenetic alopecia.
Figure 3. Acne and facial hirsutism.
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scaled from zero (no terminal hair) to four (excess hair). Above eight is regarded as hirsutism.
Additionally, acne, androgenetic alopecia, and virilization indications (clitoromegaly, muscle
mass increase, voice thickening, diminution of breast size, libido increase) should be examined.
Ferriman-Gallwey scoring system for hirsutism: upper lip, chin, chest, upper back, lower back,
upper abdomen, upper arm, forearm, and thigh/leg are the body parts used for hirsutism
diagnosis.
Figure 4. Hirsutism.
Figure 5. Acanthosis nigricans.
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At this point, the differential diagnosis of these patients is important. Late-onset congenital
adrenal hyperplasia (LOCAH) should be remembered especially in puberty patients. The use
of drugs such as methyltestosterone, anabolic steroids (norethandrolone, etc.), phenytoin,
diazoxide, danazol, cyclosporin, valproic acid, and minoxidil, which stimulate hair growth
with androgenic effect, should be questioned. In terms of Cushing’s disease, findings such as
stria, central obesity, buffalo hump, and plethora should be investigated. Galactore should be
investigated for hyperprolactinemia.
Acne is another clinical sign of hyperandrogenism. The likelihood of developing PCOS in girls
with severe acne or acne resistant to treatment may be up to 40% in adolescents [16, 17]. In
cases with persisting after adolescence, or aggravating by mid-20s, hyperandrogenemia is
common and acne can be considered a clinical sign of hyperandrogenism. However, during
adolescence, acne should not be considered a substitute for hyperandrogenism [18].
Only those with acne can have serum free T levels as well as those seen in hyperandrogenic
disease states. Likewise, hirsutism without acne is also the case [17].
Hair loss in women with hyperandrogenism is variable. Women with severe hyperandrogenemia
may experience bitemporal hair loss and loss of the frontal hairline [19].
2.2.3. Treatment options for women with hyperandrogenism
Some pharmacological agents (anti-androgens) are used to control the dermatological symptoms
of hyperandrogenism. Oral contraceptive agents can effectively reduce the androgenic effect by
increasing the sexual hormone binding globulin and/or suppressing ovarian production of
androgens. In addition, physiologic doses of dexamethasone or prednisone may directly reduce
adrenal androgen production. The basic mechanism of anti-androgen therapy is competitive
antagonism of the androgen receptor or inhibition of 5α-reductase to prevent the conversion of
testosterone to its more potent form, 5α-dihydrotestosterone. Spironolactone, cyproterone ace-
tate, and flutamide are effective with competitive antagonism and finasteride is effective with the
inhibition of 5α-reductase.
The mainstay of primary care is oral contraceptive therapy for dermatological problems in
hyperandrogenism. Oral contraceptives contain estrogen (ethinyl estradiol) and a progestin.
A 20–35 μg of daily ethinyl estradiol effectively suppresses pituitary-ovarian axis and
reduces ovarian androgen production. The ideal progestin to be used in PCOS is progestins
with the lowest androgenic profile such as chloramidon and drospirenone; however, these
may induce venous thrombosis and are contraindicated in obese patients. Oral contracep-
tives induce the synthesis of sex hormone binding protein (SHBP) from the liver and may be
more effective in controlling hirsutism and acne than transdermal or vaginal ring prepara-
tions. These formulations may be combined with anti-androgenic therapy to achieve a better
response against hirsutism. Spironolactone is an aldosterone antagonist and widely used
androgen blocker, its progestational activity may also reduce levels of the gonadotropin-
releasing hormone. Spironolactone can induce hyperkalemia. Headaches and dizziness as
side effects are relatively frequent, and the patient should increase water and salt intake
during hot weather. Spironolactone can cause intermenstrual spotting in about half of
women.
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Finasteride is a 5α-reductase inhibitor and may decrease DHT levels by 50–60%. Significant
anti-androgenic effects were shown after 6 months of treatment at 5 mg/day dose [20, 21]. The
use of 5α-reductase inhibition therapy should be considered when the previous therapy with
oral contraceptive and spironolactone is relatively ineffective [22]. Dutasteride, another anti-
androgen molecule which has limited data, reduces plasma DHT more significantly than
finasteride and inhibits the conversion of testosterone to dihydrotestosterone by the inhibition
of 5α-reductase isoenzymes [23].
Metformin is an alternative therapy for hirsutism in women with PCOS who have other
indications for the use of metformin. This oral antidiabetic drug is useful for metabolic and
glycemic anomalies and for the treatment of menstrual irregularities, but less effective than
antiandrogens for the treatment of both hirsutism and acne [22, 24].
It should be remembered that hirsutism treatment is a continuing treatment that the medical
treatment response does not occur 6 months before the hair cycle and individualization of the
treatment are necessary.
2.3. PCOS in the adolescent
PCOS commonly presents in the adolescence; underestimation may be more in this period
because of some confounding factors such as acne, menstrual irregularities, and hirsutism [25].
These factors may also be observed in normal puberty thus misdiagnosis may be common.
Anovulatory cycles and menstrual irregularities with variable cycle length are common during
first years following menarche due to the immaturity of the hypothalamic-pituitary-ovarian
axis. Additionally, large, multicystic ovaries in adolescents may also be considered normal as a
result of natural ovarian development. It may be acceptable to clinically follow the patient for
2–3 years in terms of defining the over dysfunction in adolescents [26].
Hyperandrogenism leading to acne and hirsutism may be associated with normal puberty
rather than underlying PCOS, and hyperinsulinemia is a characteristic of normal puberty.
Furthermore, ranges of laboratory values for the hyperandrogenemia and Ferriman-Gallwey
scoring system are established for adults and may not be of similar clinical importance in
adolescence.
On the other hand, symptoms in adolescents are heterogeneous and may change over time,
PCOS diagnosis may be overlooked.
In conclusion, clinical findings for PCOS in adolescents can be confusing and laboratory
measurements are important. Lower and upper bounds of testosterone are not clear in young
girls [25, 27].
2.4. PCOS and malignancy
A relationship between PCOS and malignancy has been reported in the literature, but this
relationship is not strong. The altered metabolic and hormonal environment among women
with PCOS may increase the risk of some types of cancer.
Debatable Topics in PCOS Patients16
In a systematic review by Chittenden and colleagues, they investigated the gynecological
malignancy association with PCOS and reported that women with PCOS are more likely to
develop endometrial cancer (odds ratio 2.70) and ovarian cancer (odds ratio 2.52) but not
breast cancer [28]. John et al. compared 919 women with PCOS and 72,054 women without
PCOS in their meta-analyses and reported that women of all ages with PCOS have an
increased risk of endometrial cancer (odds ratio 2.79), but the risk of ovarian and breast cancer
was not significantly increased overall [29]. Another meta-analysis by Holly et al. reported that
the associations between PCOS and endometrial, ovarian, and breast cancer are complex [30]
and argued that studies showing PCOS association with endometrial cancer do not take into
account body mass index (BMI) criteria. BMI is a strong and well-established risk factor for
endometrial cancer. In these women, the oligomenorrheic environment increases hyperplasia
and cancer risk. Prevention of oligomenorrhea by providing cyclic progesterone supplementa-
tion is important for reducing risk [31].
As a result, the risk of endometrial cancer in women with PCOS may be increased [32].
However, there is no clear association between other types of cancer and PCOS.
3. Dermatological approach to polycystic ovarian syndrome
Polycystic ovary syndrome is a multisystem disease that involves dermatologist examining
patients with clinical hyperandrogenism and/or biochemical signs of hyperandrogenism;
gynecologist examines patients with oligo-ovulation or infertility.
Although PCOS is a heterogeneous disorder without an easily identified single etiology, the
key pathophysiologic components appear to include androgen excess, abnormal gonadotropin
dynamics, and insulin resistance. Patients should be informed about long-term treatment,
including lifestyle changes with systemic treatment. Success in effective management of
women with PCOS is a synchronized effort between dermatologist, endocrinologist, obstetri-
cian, nutritionist, and physical trainer [33].
4. Treatment
Lifestyle changes, local treatment approaches, and pharmacological treatment will review
under the heading of treatment.
In cases with PCOS, lifestyle modification resulting from medical nutrition therapy and exer-
cise is effective in improving clinical signs and symptoms of hyperandrogenemia. With life-
style changes, SHBG levels increase as serum androgen levels decrease as a result of weight
loss. Stop smoking is also important to reduce the complications of oral contraceptive use [33].
Local treatment; hair removal methods such as hair bleaching, tearing, shaving, waxing, electrol-
ysis, laser hair removal, and local drug application such as eflornithine are used. It can be
applied as a single treatment in the case of localized small incisions. Medical treatment is applied
when waiting for the response. It has been shown that shaving does not increase the formation of
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new hair, and it should be explained that the illness should not underestimate this concern. It has
been shown that laser epilation can treat up to 2 years hirsutism in randomized controlled trials.
Since hair follicle stimulation continues in hyperandrogenic women, hair growth after laser
epilation repeats. About 13.9% eflornithine topical cream inhibits DNA synthesis by inhibiting
ornithine decarboxylase enzyme and suppresses the mitotic activity of the hair follicle. Terminal
hair growth begins again when the drug is stopped.
Patients with polycystic ovarian syndrome are referred to clinics of dermatology with cutaneous
androgenesis findings such as hirsutism, acne, and alopecia. For this reason, pharmacological
treatment is often required to treat hyperandrogenemia. It should be remembered that hirsutism
treatment is a continuing treatment, which the medical treatment response does not occur
6 months before the hair cycle and individualization of the treatment is necessary. Treatment
may not be necessary for the patients who do not worry about hirsutism, planning to be
pregnant, and regular menstrual cycles. OCSs are used as the only medication in mild hirsutism
cases, while OCSs are used in combination with other antiandrogen drugs in severe and moder-
ate hirsutism. Hirsutism adolescent girls respond perfectly to medical treatment. The combina-
tion of spironolactone and an oral contraceptive provides effective medical treatment. This
combination also improves spironolactone-related menstrual irregularities. If there is no
response after 6 months of treatment, the treatment should be changed. The combination of
mechanical and medical treatment provides a rapid and effective remedy. The average duration
of treatment is 2–3 years. Because the underlying cause is persistent, local or drug treatment does
not completely cease, and the complaints start again after the treatment is discontinued.
Insulin-sensitizing drugs (metformin and pioglitazone) are used in the treatment of
hyperandrogenemic patients with severe insulin resistance syndrome. It should not be used as
a primary treatment in incontinent cases. Metformin is preferred for patients with PCOS with
glucose intolerance. In these cases, metformin may contribute to other treatments on hirsutism.
Glitazones are not recommended for treatment of hirsutism due to possible cardiovascular side
effects. It is the first choice in the treatment of menstrual and ovulatory dysfunction, especially in
obese cases of lifestyle change and weight loss.
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